Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
BMJ Open Diabetes Res Care ; 9(1)2021 08.
Article in English | MEDLINE | ID: covidwho-1360558


INTRODUCTION: Achieving glycemic targets and optimizing quality of life (QoL) are important goals of type 1 diabetes care. Hypoglycemia is a common barrier to achieving targets and can be associated with significant distress. However, the impact of hypoglycemia on QoL is not fully understood. The aim of this study was to explore how adults with type 1 diabetes are impacted by hypoglycemia in areas of life that are important to their overall QoL. RESEARCH DESIGN AND METHODS: Participants responded to a web-based qualitative survey involving a novel 'Wheel of Life' activity. Responses were analyzed using reflexive thematic analysis. RESULTS: The final sample included 219 adults with type 1 diabetes from Denmark, Germany, the Netherlands, and the UK. They had a mean±SD age of 39±13 years and diabetes duration of 20±14 years. Participants identified eight areas of life important to their overall QoL, including relationships and social life, work and studies, leisure and physical activity, everyday life, sleep, sex life, physical health, and mental health. Participants reported emotional, behavioral, cognitive, and social impacts of hypoglycemia within domains. Across domains, participants described interruptions, limited participation in activities, exhaustion, fear of hypoglycemia, compensatory strategies to prevent hypoglycemia, and reduced spontaneity. CONCLUSIONS: The findings emphasize the profound impact of hypoglycemia on QoL and diabetes self-care behaviors. Diabetes services should be aware of and address the burden of hypoglycemia to provide person-centered care. Clinicians could ask individuals how hypoglycemia affects important areas of their lives to better understand the personal impact and develop tailored management plans.

Diabetes Mellitus, Type 1 , Hypoglycemia , Adult , Blood Glucose , Diabetes Mellitus, Type 1/therapy , Humans , Hypoglycemia/epidemiology , Middle Aged , Quality of Life , Surveys and Questionnaires
Lancet Diabetes Endocrinol ; 8(7): 640-648, 2020 07.
Article in English | MEDLINE | ID: covidwho-197827


The coronavirus disease 2019 pandemic is wreaking havoc on society, especially health-care systems, including disrupting bariatric and metabolic surgery. The current limitations on accessibility to non-urgent care undermine postoperative monitoring of patients who have undergone such operations. Furthermore, like most elective surgery, new bariatric and metabolic procedures are being postponed worldwide during the pandemic. When the outbreak abates, a backlog of people seeking these operations will exist. Hence, surgical candidates face prolonged delays of beneficial treatment. Because of the progressive nature of obesity and diabetes, delaying surgery increases risks for morbidity and mortality, thus requiring strategies to mitigate harm. The risk of harm, however, varies among patients, depending on the type and severity of their comorbidities. A triaging strategy is therefore needed. The traditional weight-centric patient-selection criteria do not favour cases based on actual clinical needs. In this Personal View, experts from the Diabetes Surgery Summit consensus conference series provide guidance for the management of patients while surgery is delayed and for postoperative surveillance. We also offer a strategy to prioritise bariatric and metabolic surgery candidates on the basis of the diseases that are most likely to be ameliorated postoperatively. Although our system will be particularly germane in the immediate future, it also provides a framework for long-term clinically meaningful prioritisation.

Bariatric Surgery/methods , Betacoronavirus , Coronavirus Infections/surgery , Obesity/surgery , Pandemics , Pneumonia, Viral/surgery , Postoperative Care/methods , Bariatric Surgery/trends , COVID-19 , Coronavirus Infections/epidemiology , Disease Management , Humans , Obesity/epidemiology , Pneumonia, Viral/epidemiology , Postoperative Care/trends , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , SARS-CoV-2
Lancet Diabetes Endocrinol ; 8(6): 546-550, 2020 06.
Article in English | MEDLINE | ID: covidwho-108776


Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. Depending on the global region, 20-50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate on the differential needs of several patient groups.

Betacoronavirus/pathogenicity , Coronavirus Infections/physiopathology , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/adverse effects , Pandemics , Pneumonia, Viral/physiopathology , COVID-19 , Comorbidity , Contraindications, Drug , Coronavirus Infections/therapy , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Humans , Hypoglycemic Agents/administration & dosage , Multiple Organ Failure/chemically induced , Multiple Organ Failure/physiopathology , Pneumonia, Viral/therapy , Practice Guidelines as Topic , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/physiopathology , SARS-CoV-2